Protein Kinase C in Heart Attack: From Bench to Bedside

Translational research is crux of most basic research. Dr. Daria Mochly-Rosen is one of the pioneers to have applied basic research into clinical therapy. Dr. Mochly-Rosen trained as a basic researcher with a degree in chemical immunology at the Weizmann Institute of Science in Israel followed by postdoctoral fellowship at UC Berkeley. Dr. Mochly-Rosen joined Stanford University faculty in 1993 as Professor and since then has held position as Chair of the Department of Molecular Pharmacology and most recently as Senior Associate Dean for Research. In her current role, Dr. Mochly-Rosen leads the school's effort in advancing the field of molecular pharmacology and chemical biology and its application to translational medicine. Dr. Mochly-Rosen's laboratory studies the family of enzymes called protein kinase C, which, when activated, regulate diverse functions such as heart rate, the response of the

heart and brain to stress induced by heart attack, and the regulation of cell growth in normal and cancer tissues. Research from her laboratory generated novel isozymespecific inhibitors and activators. Dr. Mochly-Rosen then took a year off from Stanford to launch a company, KAI Pharmaceuticals in South San Francisco to translate these findings into the clinic.

We would like to invite you to an exciting meeting at AWIS as Dr. Mochly-Rosen shares with us her laboratory and industry experiences.